



**As long  
as there  
are unmet  
needs,  
we keep  
working.**

We are dedicated to finding new treatments that will address the needs of those living with a central nervous system (CNS) disorder and to change the future of cancer care.

**We're SK Life Science, and we won't rest.**

---

## About SK Life Science, Inc.

---

We are a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., the first and only Korean company to develop, commercialize and market an innovative drug in the U.S., the world's largest pharmaceuticals and biotech market.

We have a unique understanding of CNS disorders and the market-specific dynamics that impact the development and commercialization of new treatments.

Since 2017, SK Biopharmaceuticals has been strategically diversifying beyond CNS to invest in oncology, helping us become a stronger company that builds upon our success.

SK Life Science and SK Biopharmaceuticals are part of SK Group, a global leader with a tradition of promoting game-changing businesses and nurturing them for long-term success. SK Group was named one of TIME's 100 Most Influential Companies of 2023.

### Our Purpose

---

We believe there is more to life when you connect health with happiness.

### Our Vision

---

#### Together, we...

- Empower Excellence
- Embody a Pioneering Spirit
- Always Do the Right Thing
- Appreciate & Recognize People
- Inspire Happiness!

### Shining a Light on the Treatment of CNS Disorders and Cancer Care

---

SK Life Science is here listening to the needs of healthcare providers, patients, caregivers, advocates, and scientists. We are developing new molecules, enhancing advocacy efforts, and providing solutions that change what's possible in the treatment of CNS disorders and cancer care.

## Committed to Next Generation Discovery


We have a deep expertise in research and development, as well as in bringing therapies to market in the U.S. We apply this expertise to the development of potential new therapies in CNS.

Together, SK Biopharmaceuticals and SK Life Science, have multiple compounds in development in CNS and oncology. With a commitment to safety, we place our patients at the center of everything we do. To address the needs of people living with a central nervous system (CNS) disorder, we are currently enrolling patients in clinical trials.

Learn more about our pipeline at:  
[www.sk Lifescienceinc.com/innovation/#pipeline](http://www.sk Lifescienceinc.com/innovation/#pipeline)

## Key Milestones in Our History

SK Biopharmaceuticals and SK Life Science independently developed an anti-seizure medication from inception through FDA approval.



**More than 170,000 patients** have been treated with our drug globally.

*Estimate derived from the use of information under license from the following IQVIA service: NPA, NSP, XPD for the period May 2020-Dec. 2023.*

In the U.S., our ASM is the **fastest-growing branded epilepsy Rx** and is first among epileptologists.

*According to NPA TRx 2023 vs 2022.*



a subsidiary of SK biopharmaceuticals

## Contact Us

---

For more information, visit us at:

[www.skifescienceinc.com](http://www.skifescienceinc.com)